Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
EMD Serono Research & Development Institute, Inc.
With
Merck KGaA, Darmstadt, Germany
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants with advanced solid tumors, for whom no standard of care therapy exists or for whom is not considered sufficiently effective, or who cannot tolerate standard of care
Participants with Eastern Cooperative Oncology Group Performance status 0 or 1
Adequate hematological, hepatic, and renal function as defined in the protocol
Participants in Part 1B (the preliminary food effect assessment) must agree to provide paired tumor biopsies if not contraindicated for medical reasons
You may not be if
Clinically significant (i.e., active) uncontrolled intercurrent illness including, but not limited to:
1. Active infection (i.e., requiring systemic antibiotics or antifungals)
2. Uncontrolled arterial hypertension
3. Severe cardiac arrhythmia requiring medication
4. Cerebral vascular accident/stroke
Has known ataxia telangiectasia
Participants with tumors harboring previously identified ATM mutations
Participants with hypersensitivity to the active substance or to any of the excipients of M4076
Clareo Health | First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)
